AstraZeneca’s $ 39 billion takeover of rare disease specialist Alexion has another regulatory blessing in the bag, but the pair are still holding out for a key nod from the U.K. to settle the deal. AstraZeneca on Tuesday said that the European Union has approved its acquisition of Boston-based Alexion, inching closer toward its goal… Read More »
Alexion has big goals for Soliris follow-up Ultomiris in paroxysmal nocturnal hemoglobinuria (PNH), and wooing patients over from predecessor Soliris is key. But so far, executives say, those aims are right on track. As of the end of January—the first full month of the newcomer’s rollout after its Dec. 27 approval—Alexion had switched about 5%… Read More »
SAN FRANCISCO—In 2019, Alexion is looking to pivot from an ultrarare-disease company to a rare-disease company—and it knows its pricing strategy has to change. With its top-selling therapy, Soliris, the company is moving into new diseases that aren’t nearly as rare as its previous targets. The drug recently nabbed an approval in generalized myasthenia gravis and is looking… Read More »